213 related articles for article (PubMed ID: 28947138)
1. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract][Full Text] [Related]
2. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
6. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer subtypes: a roadmap for precision medicine.
Torres C; Grippo PJ
Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
[TBL] [Abstract][Full Text] [Related]
10. [Organoids from pancreatic ductal adenocarcinoma].
Dusetti N; Iovanna J
Med Sci (Paris); 2020 Jan; 36(1):57-62. PubMed ID: 32014099
[TBL] [Abstract][Full Text] [Related]
11. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.
Allaway RJ; Fischer DA; de Abreu FB; Gardner TB; Gordon SR; Barth RJ; Colacchio TA; Wood M; Kacsoh BZ; Bouley SJ; Cui J; Hamilton J; Choi JA; Lange JT; Peterson JD; Padmanabhan V; Tomlinson CR; Tsongalis GJ; Suriawinata AA; Greene CS; Sanchez Y; Smith KD
Oncotarget; 2016 Mar; 7(13):17087-102. PubMed ID: 26934555
[TBL] [Abstract][Full Text] [Related]
12. Genomics of pancreatic ductal adenocarcinoma.
Pilarsky C; Grutzmann R
Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma.
Duconseil P; Gilabert M; Gayet O; Loncle C; Moutardier V; Turrini O; Calvo E; Ewald J; Giovannini M; Gasmi M; Bories E; Barthet M; Ouaissi M; Goncalves A; Poizat F; Raoul JL; Secq V; Garcia S; Viens P; Iovanna J; Dusetti N
Am J Pathol; 2015 Apr; 185(4):1022-32. PubMed ID: 25765988
[TBL] [Abstract][Full Text] [Related]
14. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
[TBL] [Abstract][Full Text] [Related]
15. [An "a la carte" treatment for patients with pancreatic adenocarcinoma].
Iovanna J; Dusetti N
Medicina (B Aires); 2022; 82(4):571-573. PubMed ID: 35904914
[TBL] [Abstract][Full Text] [Related]
16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
17. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
Witkiewicz AK; Balaji U; Eslinger C; McMillan E; Conway W; Posner B; Mills GB; O'Reilly EM; Knudsen ES
Cell Rep; 2016 Aug; 16(7):2017-31. PubMed ID: 27498862
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Nicolle R; Blum Y; Duconseil P; Vanbrugghe C; Brandone N; Poizat F; Roques J; Bigonnet M; Gayet O; Rubis M; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Giovannini M; Grandval P; Garcia S; Canivet C; Cros J; Bournet B; Buscail L; ; Moutardier V; Gilabert M; Iovanna J; Dusetti N
EBioMedicine; 2020 Jul; 57():102858. PubMed ID: 32629389
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
20. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
[Next] [New Search]